Vigil Neuroscience (VIGL)
(Delayed Data from NSDQ)
$8.05 USD
0.00 (0.00%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $8.06 +0.01 (0.12%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth C Momentum D VGM
Fundamental Charts
About Market Cap
As of the previous market close, Vigil Neuroscience, Inc. has a market cap of $383.88M, which represents its share price of $8.05 multiplied by its outstanding shares number of 47.69M. As a small-cap company, VIGL's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
VIGL 8.05 0.00(0.00%)
Will VIGL be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for VIGL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VIGL
Sanofi Q2 Earnings & Sales Miss, 2025 Top-Line View Raised, Stock Down
Wall Street Analysts See a 26.1% Upside in Vigil Neuroscience (VIGL): Can the Stock Really Move This High?
VIGL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts Think Vigil Neuroscience (VIGL) Could Surge 26.9%: Read This Before Placing a Bet
Should You Buy Vigil Neuroscience, Inc. (VIGL) After Golden Cross?
Wall Street Analysts Believe Vigil Neuroscience (VIGL) Could Rally 86.68%: Here's is How to Trade
Other News for VIGL
Catalyst Watch: Palantir earnings, Firefly Aerospace IPO, OPEC+, and the Fed's SLOOS report
Eli Lilly's Early Alzheimer's Drug Recommended For Approval By European Drug Regulator's Panel
Tesla, Alphabet Set To Report Earnings As Investors Watch Out For Jobless Claims And Durable Goods Orders
Catalyst Watch: Alphabet earnings, McGraw Hill IPO, Trump talks AI, and more robotaxi buzz
Vigil Neuroscience: ALSP Data Doesn't Deliver, But Sanofi Purchase Remains Intact